Malignant peripheral nerve sheath tumors in neurofibromatosis 1.

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10

Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet (2002) 5.06

Functional copy-number alterations in cancer. PLoS One (2008) 4.27

Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet (2001) 2.78

BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells. PLoS One (2014) 1.50

Malignant peripheral nerve sheath tumours in neurofibromatosis type 1: MRI supports the diagnosis of malignant plexiform neurofibroma. Neuroradiology (2003) 1.29

Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J Pathol (2010) 1.29

BET bromodomain inhibition triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors through Bim induction. Cell Rep (2013) 1.01

Differentiation between neurofibromas and malignant peripheral nerve sheath tumors in neurofibromatosis 1 evaluated by MRI. J Cancer Res Clin Oncol (2008) 1.00

Recurrent chromosomal imbalances and structurally abnormal breakpoints within complex karyotypes of malignant peripheral nerve sheath tumour and malignant triton tumour: a cytogenetic and molecular cytogenetic study. J Clin Pathol (2004) 1.00

MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression. Br J Cancer (2012) 0.99

MicroRNA-204 critically regulates carcinogenesis in malignant peripheral nerve sheath tumors. Neuro Oncol (2012) 0.98

Neoplasms associated with germline and somatic NF1 gene mutations. Oncologist (2012) 0.95

Utility of 18F-FDG PET with a semi-quantitative index in the detection of sarcomatous transformation in patients with neurofibromatosis type 1. PLoS One (2014) 0.81

Soft tissue sarcomas and central nervous system tumors in children with neurofibromatosis type 1. Childs Nerv Syst (2011) 0.79

Malignant peripheral nerve sheath tumors in children with neurofibromatosis type 1. Case Rep Oncol Med (2014) 0.78

Application of proteomics to soft tissue sarcomas. Int J Proteomics (2012) 0.75

Malignant Peripheral Nerve Sheath Tumor of the C2 Nerve Root: Case Report. J Neurol Surg Rep (2017) 0.75

Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors. Oncotarget (2016) 0.75

The correlation between clinical, nuclear and histologic findings in a patient with Von Recklinghausen's disease. World J Surg Oncol (2007) 0.75

Malignant nerve sheath tumor involving glossopharyngeal, vagus and spinal nerve with intracranial-extracranial extension and systemic metastases in a patient with type 1 neurofibromatosis: A case report. Int J Surg Case Rep (2016) 0.75

Use of liquid biopsies to monitor disease progression in a sarcoma patient: a case report. BMC Cancer (2017) 0.75

Malignant peripheral nerve sheath tumors in Africa: a clinicopathological study. ISRN Surg (2011) 0.75

Malignant peripheral nerve sheath tumor of proximal third tibia. World J Clin Oncol (2015) 0.75

Malignant peripheral nerve cell sheath tumour of the upper lip: a rare case. J Surg Case Rep (2010) 0.75

Role of ultrasonography in detection of renal artery pseudoaneurysm caused by retroperitoneal malignant peripheral nerve sheath tumor in a patient with neurofibromatosis type 1. J Med Ultrason (2001) (2013) 0.75

Von Recklinghausen neurofibromatosis. N Engl J Med (1981) 7.69

Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature (1992) 4.42

Deletions of chromosome 15 as a cause of the Prader-Willi syndrome. N Engl J Med (1981) 4.25

The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev (2001) 3.65

ASHG activities relative to education: Human genetics as a component of medical school curricula: A report to the American society of human genetics. Am J Hum Genet (1988) 3.24

Chromosomal imbalance in the Aniridia-Wilms' tumor association: 11p interstitial deletion. Pediatrics (1978) 3.04

Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci U S A (1990) 2.52

Chromosome 15 abnormalities and the Prader-Willi syndrome: a follow-up report of 40 cases. Am J Hum Genet (1982) 2.44

Neurofibromatosis: clinical heterogeneity. Curr Probl Cancer (1982) 2.43

Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol (1997) 2.28

Aniridia-Wilms' tumor association: evidence for specific deletion of 11p13. Cytogenet Cell Genet (1979) 2.18

Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res (2001) 2.13

cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. Genomics (1991) 2.03

Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma. Neurology (2009) 2.00

Plexiform neurofibromas in NF1: toward biologic-based therapy. Neurology (2002) 1.90

High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas. Oncogene (2008) 1.84

Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet (1996) 1.70

Familial retinoblastoma and chromosome 13 deletion transmitted via an insertional translocation. Science (1981) 1.70

Report of the Task Force on Teaching Human Genetics in North American Medical Schools. Am J Hum Genet (1989) 1.65

The pathophysiology of neurofibromatosis: IX. Paternal age as a factor in the origin of new mutations. Am J Med Genet (1984) 1.60

Deletions spanning the neurofibromatosis 1 gene: identification and phenotype of five patients. Am J Hum Genet (1994) 1.56

Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene (1997) 1.55

Von Recklinghausen neurofibromatosis. Incidence of iris hamartomata. Ophthalmology (1981) 1.55

Cancer-related gene expression profiles in NF1-associated pilocytic astrocytomas. Neurology (2001) 1.54

Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines. Nat Genet (1993) 1.45

Differential effects of cAMP in neurons and astrocytes. Role of B-raf. J Biol Chem (1999) 1.43

A conserved alternative splice in the von Recklinghausen neurofibromatosis (NF1) gene produces two neurofibromin isoforms, both of which have GTPase-activating protein activity. Mol Cell Biol (1993) 1.43

Skin, blood, nerve cells, and heritability. New lessons from neurofibromatosis type 1. Arch Dermatol (1995) 1.40

Health care and disease prevention through genetic counseling: a regional approach. Am J Public Health (1976) 1.37

von Recklinghausen neurofibromatosis. II. Incidence of optic gliomata. Ophthalmology (1984) 1.32

Intracranial gliomas in neurofibromatosis type 1. Am J Med Genet (1999) 1.29

Angiogenic and invasive properties of neurofibroma Schwann cells. J Cell Biol (1990) 1.28

Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1. Hum Mol Genet (2000) 1.27

The FG syndrome: further characterization, report of a third family, and of a sporadic case. Am J Med Genet (1977) 1.27

Gene dose effect: intraband mapping of the LDH A locus using cells from four individuals with different interstitial deletions of 11p. Cytogenet Cell Genet (1977) 1.27

Neurofibromatosis: variable expression is not intrinsic to the mutant gene. Birth Defects Orig Artic Ser (1979) 1.26

Reduction of biogenic amine levels in the Rett syndrome. N Engl J Med (1985) 1.26

Mammalian target of rapamycin: master regulator of cell growth in the nervous system. Histol Histopathol (2007) 1.22

Oculocutaneous albinoidism as a manifestation of reduced neural crest derivatives in the Prader-Willi syndrome. Am J Ophthalmol (1982) 1.22

Merlin differentially associates with the microtubule and actin cytoskeleton. J Neurosci Res (1998) 1.21

Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases. J Neuropathol Exp Neurol (2001) 1.21

Neurofibromatosis: past, present, and future. N Engl J Med (1991) 1.21

Long range physical map of the Wilms' tumor-aniridia region on human chromosome 11. Cell (1988) 1.18

Mast-cell stabilization to decrease neurofibroma growth. Preliminary experience with ketotifen. Arch Dermatol (1987) 1.18

Late-onset optic pathway tumors in children with neurofibromatosis 1. Neurology (2004) 1.17

NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors. Am J Pathol (2001) 1.16

Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases. J Neuropathol Exp Neurol (2000) 1.16

Preventive medicine through genetic counseling: a regional program. Prev Med (1975) 1.15

Neurofibromatosis: oral and radiographic manifestations. Oral Surg Oral Med Oral Pathol (1984) 1.15

Cervical cord compression from plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry (2007) 1.14

Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma. J Neuropathol Exp Neurol (2000) 1.14

Trisomy 8: an international study of 70 patients. Birth Defects Orig Artic Ser (1977) 1.13

Genetic mechanisms of tumor-specific loss of 11p DNA sequences in Wilms tumor. Am J Hum Genet (1987) 1.10

Parental origin of de novo constitutional deletions of chromosomal band 11p13. Am J Hum Genet (1990) 1.10

Preferential mutation of the neurofibromatosis type 1 gene in paternally derived chromosomes. Hum Genet (1992) 1.09

Matrilin-2 expression distinguishes clinically relevant subsets of pilocytic astrocytoma. Neurology (2006) 1.09

Clinic-based study of plexiform neurofibromas in neurofibromatosis 1. Am J Med Genet (2000) 1.09

The generation and characterization of a cell line derived from a sporadic renal angiomyolipoma: use of telomerase to obtain stable populations of cells from benign neoplasms. Am J Pathol (2001) 1.08

Neurofibromatosis: a neoplastic birth defect with two age peaks of severe problems. Birth Defects Orig Artic Ser (1977) 1.07

Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes. Oncogene (2011) 1.05

Linkage studies with chromosome 17 DNA markers in 45 neurofibromatosis 1 families. Genomics (1987) 1.05

Cutaneous manifestation of neurofibromatosis: cellular interaction, pigmentation, and mast cells. Birth Defects Orig Artic Ser (1981) 1.04

Genotype, malleotype, phenotype, and randomness: lessons from neurofibromatosis-1 (NF-1) Am J Hum Genet (1993) 1.03

Large de novo DNA deletion in a patient with sporadic neurofibromatosis 1, mental retardation, and dysmorphism. J Med Genet (1992) 1.03

Expression of the neurofibromatosis I gene product, neurofibromin, in blood vessel endothelial cells and smooth muscle. Neurobiol Dis (1995) 1.02

Genetic mosaicism in normal tissues of Wilms' tumour patients. Nat Genet (1993) 1.02

Aniridia caused by a heritable chromosome 11 deletion. Ophthalmology (1979) 1.02

Familial spinal neurofibromatosis: clinical and DNA linkage analysis. Neurology (1991) 1.02

Chromosome translocations in couples with multiple spontaneous abortions. Am J Hum Genet (1982) 1.01

De novo 13q paracentric inversion in a boy with cleft palate and mental retardation. Hum Genet (1979) 1.01

Familial cavernous angiomas: natural history and genetic study over a 5-year period. Am J Med Genet (1982) 1.01

Discounting an adverse maternal effect on severity of neurofibromatosis. Pediatrics (1987) 1.00

Partial triplication and deletion of 13q: study of a family presenting with bilateral retinoblastomas. Clin Genet (1979) 1.00

Neurofibromatosis 1 (NF1) heterozygosity results in a cell-autonomous growth advantage for astrocytes. Glia (2001) 0.99

Spondylohumerofemoral hypoplasia (giant cell chondrodysplasia): a neonatally lethal short-limbed skeletal displasia. Am J Med Genet (1982) 0.99

Variable expressivity in autosomal dominant aniridia by clinical, electrophysiologic, and angiographic criteria. Am J Ophthalmol (1980) 0.99

Associations of clinical features in neurofibromatosis 1 (NF1). Genet Epidemiol (2000) 0.99

Neurofibromatosis type 1 gene product (neurofibromin) associates with microtubules. Somat Cell Mol Genet (1993) 0.99

Ocular abnormalities in neurofibromatosis 2. Am J Ophthalmol (1995) 0.99

Amniotic fluid concentrations of delta 5 and delta 4 steroids in fetuses with congenital adrenal hyperplasia due to 21 hydroxylase deficiency and in anencephalic fetuses. J Clin Endocrinol Metab (1980) 0.98

Café au lait spots: the pediatrician's perspective. Pediatr Rev (2001) 0.98

The EWSR1/NR4A3 fusion protein of extraskeletal myxoid chondrosarcoma activates the PPARG nuclear receptor gene. J Pathol (2009) 0.97

Tumorigenesis in neurofibromatosis: new insights and potential therapies. Trends Mol Med (2001) 0.97

Possible misdiagnosis of Krabbe disease. J Pediatr (1976) 0.97

Duplication of proximal 15q as a cause of Prader-Willi syndrome. Am J Med Genet (1987) 0.97

Neoplasms in neurofibromatosis 1 are related to gender but not to family history of cancer. Genet Epidemiol (2001) 0.97

Ultrastructural characterization of the optic pathway in a mouse model of neurofibromatosis-1 optic glioma. Neuroscience (2010) 0.96

Pathophysiology of neurofibromatosis. IV. Dermatologic insights into heterogeneity and pathogenesis. J Am Acad Dermatol (1980) 0.96

Neurofibromatosis: an overview and new directions in clinical investigations. Adv Neurol (1981) 0.95

miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells. Oncogene (2012) 0.95

The role of surgical biopsy in the diagnosis of glioma in individuals with neurofibromatosis-1. Neurology (2006) 0.95

The ocular presentation of neurofibromatosis 2. Eye (Lond) (1997) 0.94

Mapping parathyroid hormone, beta-globin, insulin, and LDH-A genes within the human chromosome 11 short arm by spot blotting sorted chromosomes. Hum Genet (1985) 0.94

Mutations in the GAP-related domain impair the ability of neurofibromin to associate with microtubules. Brain Res (1997) 0.94

Absent patellae, mild mental retardation, skeletal and genitourinary anomalies, and C group autosomal mosaicism. J Pediatr (1970) 0.94

Ezrin, radixin, and moesin are components of Schwann cell microvilli. J Neurosci Res (2001) 0.94

Expression of the neurofibromatosis 2 tumor suppressor gene product, merlin, in Schwann cells. J Neurosci Res (1996) 0.94

Phosphorylation of neurofibromin by PKC is a possible molecular switch in EGF receptor signaling in neural cells. Oncogene (2006) 0.93

Expression of a developmentally-regulated neuron-specific isoform of the neurofibromatosis 1 (NF1) gene. Neurosci Lett (1996) 0.93

Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas. Vet Pathol (2009) 0.92